Shanghai ChemPartner, one of ShangPharma’s several subsidiaries, said its scientists contributed to the breakthrough cancer research announced by Agios Pharmaceuticals, with whom ChemPartner has an ongoing relationship. In the November 22 online issue of Nature, Agios scientists published an article entitled "Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2HG)." Their research, at least partly carried out at ChemPartner, showed the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene, revealing new possibilities for novel cancer treatments. More details...